 MutS Homolog 2 Protein
"MutS Homolog 2 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A highly conserved eukaryotic homolog of the MUTS DNA MISMATCH-BINDING PROTEIN. It plays an essential role in meiotic RECOMBINATION and DNA REPAIR of mismatched NUCLEOTIDES.
| Descriptor ID |
D051718
|
| MeSH Number(s) |
D08.811.074.844.750 D08.811.277.040.025.292.750 D12.776.260.556.750 D12.776.624.664.700.130
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "MutS Homolog 2 Protein".
Below are MeSH descriptors whose meaning is more specific than "MutS Homolog 2 Protein".
This graph shows the total number of publications written about "MutS Homolog 2 Protein" by people in this website by year, and whether "MutS Homolog 2 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2008 | 1 | 1 | 2 | | 2014 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "MutS Homolog 2 Protein" by people in Profiles.
-
Pozdeyev N, Erickson TA, Zhang L, Ellison K, Rivard CJ, Sams S, Hirsch FR, Haugen BR, French JD. Comprehensive Immune Profiling of Medullary Thyroid Cancer. Thyroid. 2020 09; 30(9):1263-1279.
-
Kahn RM, Gordhandas S, Maddy BP, Baltich Nelson B, Askin G, Christos PJ, Caputo TA, Chapman-Davis E, Holcomb K, Frey MK. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population? Cancer. 2019 09 15; 125(18):3172-3183.
-
Pathak SJ, Mueller JL, Okamoto K, Das B, Hertecant J, Greenhalgh L, Cole T, Pinsk V, Yerushalmi B, Gurkan OE, Yourshaw M, Hernandez E, Oesterreicher S, Naik S, Sanderson IR, Axelsson I, Agardh D, Boland CR, Martin MG, Putnam CD, Sivagnanam M. EPCAM mutation update: Variants associated with congenital tufting enteropathy and Lynch syndrome. Hum Mutat. 2019 02; 40(2):142-161.
-
Goodspeed A, Jean A, Costello JC. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer. Eur Urol. 2019 02; 75(2):242-250.
-
Deihimi S, Lev A, Slifker M, Shagisultanova E, Xu Q, Jung K, Vijayvergia N, Ross EA, Xiu J, Swensen J, Gatalica Z, Andrake M, Dunbrack RL, El-Deiry WS. BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. Oncotarget. 2017 Jun 20; 8(25):39945-39962.
-
Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S, Chang DK, Miller DK, Pajic M, Kassahn KS, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Stone A, Wilson PJ, Anderson M, Fink JL, Holmes O, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Mead RS, Xu Q, Wu J, Pinese M, Cowley MJ, Jones MD, Nagrial AM, Chin VT, Chantrill LA, Mawson A, Chou A, Scarlett CJ, Pinho AV, Rooman I, Giry-Laterriere M, Samra JS, Kench JG, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, McKay CJ, Carter CR, Dickson EJ, Graham JS, Duthie F, Oien K, Hair J, Morton JP, Sansom OJ, Gr?tzmann R, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Rusev B, Corbo V, Salvia R, Cataldo I, Tortora G, Tempero MA, Hofmann O, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Gill AJ, Pearson JV, Grimmond SM, Waddell N, Biankin AV. Hypermutation In Pancreatic Cancer. Gastroenterology. 2017 01; 152(1):68-74.e2.
-
Chen Z, Eder MD, Elos MT, Viboolsittiseri SS, Chen X, Wang JH. Interplay between Target Sequences and Repair Pathways Determines Distinct Outcomes of AID-Initiated Lesions. J Immunol. 2016 Mar 01; 196(5):2335-47.
-
Ait Ouakrim D, Dashti SG, Chau R, Buchanan DD, Clendenning M, Rosty C, Winship IM, Young JP, Giles GG, Leggett B, Macrae FA, Ahnen DJ, Casey G, Gallinger S, Haile RW, Le Marchand L, Thibodeau SN, Lindor NM, Newcomb PA, Potter JD, Baron JA, Hopper JL, Jenkins MA, Win AK. Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome. J Natl Cancer Inst. 2015 Sep; 107(9).
-
Clay MR, Allison KH, Folkins AK, Longacre TA. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency. Am J Surg Pathol. 2014 Nov; 38(11):1494-500.
-
Dowty JG, Win AK, Buchanan DD, Lindor NM, Macrae FA, Clendenning M, Antill YC, Thibodeau SN, Casey G, Gallinger S, Marchand LL, Newcomb PA, Haile RW, Young GP, James PA, Giles GG, Gunawardena SR, Leggett BA, Gattas M, Boussioutas A, Ahnen DJ, Baron JA, Parry S, Goldblatt J, Young JP, Hopper JL, Jenkins MA. Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat. 2013 Mar; 34(3):490-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|